Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c

Biochemical and Biophysical Research Communications

Volumn 404, Issue 2, 2011, Pages 622-627

  Guo, Xiaobo ^a   Jing, Changqing ^a   Li, Leping ^a   Zhang, Li ^a   Shi, Yulong ^a   Wang, Jinshen ^a   Liu, Jinglei ^a   Li, Chensheng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Expression; Gastric cancer; Methylation; MicroRNA; VEZT gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADHERENS JUNCTION TRANSMEMBRANE PROTEIN; BISULFITE; LUCIFERASE; MEMBRANE PROTEIN; MESSENGER RNA; MICRORNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

3' UNTRANSLATED REGIONS; AZACITIDINE; BASE SEQUENCE; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEK293 CELLS; HUMANS; LUCIFERASES; MEMBRANE PROTEINS; MICRORNAS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

EID: 78651359052     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.026     Document Type: Article

References (32)

1. Compare D., Rocco A., Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010, 14:302-308.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
3. Petrocca F., Visone R., Onelli M.R., Shah M.H., Nicoloso M.S., de Martino I., Iliopoulos D., Pilozzi E., Liu C.G., Negrini M., Cavazzini L., Volinia S., Alder H., Ruco L.P., Baldassarre G., Croce C.M., Vecchione A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
4. Kussel-Andermann P., El-Amraoui A., Safieddine S., Nouaille S., Perfettini I., Lecuit M., Cossart P., Wolfrum U., Petit C. Vezatin, a novel transmembrane protein bridges myosin VIIA to the cadherin-catenins complex. EMBO J. 2000, 19:6020-6029.
5. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 2007, 16:R50-R59. Spec. No. 1.
6. Jones P.A., Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001, 293:1068-1070.
7. Katada T., Ishiguro H., Kuwabara Y., Kimura M., Mitui A., Mori Y., Ogawa R., Harata K., Fujii Y. microRNA expression profile in undifferentiated gastric cancer. Int. J. Oncol. 2009, 34:537-542.
8. Kawakami K., Brabender J., Lord R.V., Groshen S., Greenwald B.D., Krasna M.J., Yin J., Fleisher A.S., Abraham J.M., Beer D.G., Sidransky D., Huss H.T., Demeester T.R., Eads C., Laird P.W., Ilson D.H., Kelsen D.P., Harpole D., Moore M.B., Danenberg K.D., Danenberg P.V., Meltzer S.J. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 2000, 92:1805-1811.
9. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
10. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
11. Bueno M.J., de Castro I.P., Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008, 7:3143-3148.
12. Cho W.C. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 2007, 6:60.
13. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003, 4:351-358.
14. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
15. Lemaire M., Chabot G.G., Raynal N.J., Momparler L.F., Hurtubise A., Bernstein M.L., Momparler R.L. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 2008, 8:128.
16. Jee C.D., Kim M.A., Jung E.J., Kim J., Kim W.H. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur. J. Cancer 2009, 45:1282-1293.
17. Momparler R.L. Cancer epigenetics. Oncogene 2003, 22:6479-6483.
18. Telford J.L., Covacci A., Ghiara P., Montecucco C., Rappuoli R. Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. Trends Biotechnol. 1994, 12:420-426.
19. Ushijima T., Nakajima T., Maekita T. DNA methylation as a marker for the past and future. J. Gastroenterol. 2006, 41:401-407.
20. Li Z., Zhan W., Wang Z., Zhu B., He Y., Peng J., Cai S., Ma J. Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem. Biophys. Res. Commun. 2006, 348:229-237.
21. Tie J., Pan Y., Zhao L., Wu K., Liu J., Sun S., Guo X., Wang B., Gang Y., Zhang Y., Li Q., Qiao T., Zhao Q., Nie Y., Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010, 6:e1000879.
22. Wang Z., He Y.L., Cai S.R., Zhan W.H., Li Z.R., Zhu B.H., Chen C.Q., Ma J.P., Chen Z.X., Li W., Zhang L.J. Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference. Int. J. Cancer 2008, 123:1439-1447.
23. Choi I.S., Wu T.T. Epigenetic alterations in gastric carcinogenesis. Cell Res. 2005, 15:247-254.
24. Robertson K.D., Jones P.A. DNA methylation: past, present and future directions. Carcinogenesis 2000, 21:461-467.
25. Toyota M., Issa J.P. Epigenetic changes in solid and hematopoietic tumors. Semin. Oncol. 2005, 32:521-530.
26. Cairns P. 5'-Azacytidine expression arrays. Methods Mol. Biol. 2009, 507:165-174.
27. Hellebrekers D.M., Melotte V., Vire E., Langenkamp E., Molema G., Fuks F., Herman J.G., Van Criekinge W., Griffioen A.W., van Engeland M. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007, 67:4138-4148.
28. Hurtubise A., Bernstein M.L., Momparler R.L. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int. 2008, 8:16.
29. Schneider-Stock R., Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 2007, 10:557-561.
30. Sethupathy P., Megraw M., Hatzigeorgiou A.G. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods 2006, 3:881-886.
31. Iizuka N., Oka M., Yamada-Okabe H., Nishida M., Maeda Y., Mori N., Takao T., Tamesa T., Tangoku A., Tabuchi H., Hamada K., Nakayama H., Ishitsuka H., Miyamoto T., Hirabayashi A., Uchimura S., Hamamoto Y. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003, 361:923-929.
32. Roberts L.R., Gores G.J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 2005, 25:212-225.